Plasmid DNA manufacturing market to grow at 18% CAGR, reaching $10.8B by 2034 driven by gene therapy demand

The global plasmid DNA manufacturing market is projected to grow at a compound annual growth rate (CAGR) of approximately 18% from 2026 to 2034, reaching a market size of $10.8 billion. This growth is fueled by increasing demand for gene therapies, DNA vaccines, and cell-based therapies like CAR-T, alongside expanding mRNA vaccine production. Key regions leading this growth include North America, Europe, and Asia-Pacific, supported by investments in GMP-compliant manufacturing and technological advancements. Major biopharma companies are expanding capacity to meet rising clinical and commercial demand, signaling strong market momentum in genetic medicine manufacturing.